


CLAIMS

WHAT IS CLAIMED IS:

1. A compound having the Formula (I), or a pharmaceutically acceptable salt or solvate thereof:



Formula (I);


wherein:


R¹ is selected from the group consisting of hydrogen, halogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C₃-C₈cycloalkyl, optionally substituted -(C₁-C₂alkylene)-(C₃-C₈cycloalkyl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted -(C₁-C₂alkylene)-(C₂-C₉heterocycloalkyl), optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted -(C₁-C₂alkylene)-(heteroaryl), -OR¹⁰, -SR¹⁰, -N(R¹¹)R¹², -N(R¹¹)S(O)₂R¹⁵; -N(R¹³)N(R¹¹)R¹², -N(R¹³)N(R¹¹)S(O)₂R¹⁵, -C(O)R¹⁴, -C(O)OR¹⁰, -C(S)OR¹⁰, -C(O)SR¹⁰, -C(O)N(R¹¹)R¹², -C(S)N(R¹¹)R¹², -C(O)N(R¹¹)S(O)₂R¹⁵, -C(S)N(R¹¹)S(O)₂R¹⁵, -C(O)N(R¹³)N(R¹¹)R¹², -C(S)N(R¹³)N(R¹¹)R¹² and -C(O)N(R¹³)N(R¹¹)S(O)₂R¹⁵;

R² is selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted heteroaryl, optionally substituted C₂-C₉heterocycloalkyl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl);

R³ is selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-

C₂alkylene)-(aryl), optionally substituted heteroaryl, optionally substituted C₂-C₉heterocycloalkyl, optionally substituted -(C₁-C₂alkylene)-(heteroaryl), -C(O)R²⁰, -C(O)OR²⁰, -S(O)₂R²⁰, -C(O)N(R²¹)R²², -C(O)N(R²¹)S(O)₂R²⁴, -C(O)N(R²³)N(R²¹)R²², -C(O)N(R²³)N(R²¹)S(O)₂R²⁴, -N(R²³)C(O)R²⁰, -N(R²³)C(O)N(R²¹)R²², -N(R²³)C(O)N(R²¹)S(O)₂R²⁴, -N(R²⁰)C(O)N(R²³)N(R²¹)R²², -N(R²³)C(O)OR²⁰, -P(O)OR²⁰, and -P(O)(OR¹⁹)OR²⁰; R⁴, R⁵, R⁶, and R⁷ are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, and optionally substituted C₂-C₆alkynyl;

R⁸ is selected from the group consisting of -CN, -C(O)OR²⁵, -C(O)N(R²⁵)R²⁶, ,

and  ;

R¹⁰, R¹³ and R¹⁴ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl);

R¹¹ and R¹² are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl); or optionally R¹¹ and R¹² together with the nitrogen atom to which they are attached, form an optionally substituted C₂-C₉heterocycloalkyl ring;

R¹⁵ is selected from the group consisting of optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl),

optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl);


R¹⁹, R²⁰, and R²³ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl);

R²¹ and R²² are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl); or optionally R²¹ and R²² together with the nitrogen atom to which they are attached, form an optionally substituted C₂-C₉heterocycloalkyl ring;

R²⁴ is selected from the group consisting of optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl); and

R²⁵ and R²⁶ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl).

2. The compound according to claim 1 having a structure of Formula (IX), or a pharmaceutically acceptable salt or solvate thereof:



(IX)

wherein:

R^1 is selected from the group consisting of hydrogen, halogen, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, optionally substituted C_2 - C_6 alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C_3 - C_8 cycloalkyl, optionally substituted $-(C_1-C_2\text{alkylene})-(C_3-C_8\text{cycloalkyl})$, optionally substituted C_2 - C_9 heterocycloalkyl, optionally substituted $-(C_1-C_2\text{alkylene})-(C_2-C_9\text{heterocycloalkyl})$, optionally substituted $-(C_1-C_2\text{alkylene})-(\text{aryl})$, optionally substituted $-(C_1-C_2\text{alkylene})-(\text{heteroaryl})$, $-OR^{10}$, $-SR^{10}$, $-N(R^{11})R^{12}$, $-N(R^{11})S(O)_2R^{15}$, $-N(R^{13})N(R^{11})R^{12}$, $-N(R^{13})N(R^{11})S(O)_2R^{15}$, $-C(O)R^{14}$, $-C(O)OR^{10}$, $-C(S)OR^{10}$, $-C(O)SR^{10}$, $-C(O)N(R^{11})R^{12}$, $-C(S)N(R^{11})R^{12}$, $-C(O)N(R^{11})S(O)_2R^{15}$, $-C(S)N(R^{11})S(O)_2R^{15}$, $-C(O)N(R^{13})N(R^{11})R^{12}$, $-C(S)N(R^{13})N(R^{11})R^{12}$ and $-C(O)N(R^{13})N(R^{11})S(O)_2R^{15}$;

R^2 is selected from the group consisting of hydrogen, optionally substituted C_1 - C_6 alkyl, optionally substituted C_3 - C_8 cycloalkyl, optionally substituted aryl, optionally substituted $-(C_1-C_2\text{alkylene})-(\text{aryl})$, optionally substituted heteroaryl, optionally substituted C_2 - C_9 heterocycloalkyl, and optionally substituted $-(C_1-C_2\text{alkylene})-(\text{heteroaryl})$;

R^4 and R^5 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, and optionally substituted C_2 - C_6 alkynyl;

R^6 and R^7 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, and optionally substituted C_2 - C_6 alkynyl;

R^8 is $-C(O)OR^{25}$ or $-C(O)N(R^{25})R^{26}$;

R¹⁰, R¹³ and R¹⁴ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl);

R¹¹ and R¹² are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl); or optionally R¹¹ and R¹² together with the nitrogen atom to which they are attached, form an optionally substituted C₂-C₉heterocycloalkyl ring;

R¹⁵ is selected from the group consisting of optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, optionally substituted C₂-C₆alkynyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl);

R²⁵ and R²⁶ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₆alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted aryl, optionally substituted -(C₁-C₂alkylene)-(aryl), optionally substituted C₂-C₉heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted -(C₁-C₂alkylene)-(heteroaryl);


R³⁰ is halogen, optionally substituted -(C₁-C₄alkylene)-(C₂-C₉heterocycloalkyl), or optionally substituted -O-(C₁-C₄alkylene)-(C₂-C₉heterocycloalkyl);

each R³¹ is independently halogen, -OH, -CN, -NO₂, -NH₂, optionally substituted C₁-C₆alkyl, optionally substituted C₁-C₆alkoxy, optionally substituted C₁-C₆alkylamine, optionally substituted C₃-C₈cycloalkyl, optionally substituted C₂-C₉heterocycloalkyl, aryl, or heteroaryl; and


n is 0, 1, 2, 3, or 4.

3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R¹ is optionally substituted C₁-C₆alkyl, optionally substituted C₂-C₆alkenyl, or optionally substituted C₂-C₆alkynyl.
4. The compound of claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein R¹ is optionally substituted C₁-C₆alkyl and R² is H.
5. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R³ is -C(O)R²⁰.
6. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof wherein R⁴ and R⁵ are each independently optionally substituted C₁-C₆alkyl and R⁶ and R⁷ are each hydrogen.
7. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R⁸ is -C(O)OR²⁵.
8. The compound of claim 5, or a pharmaceutically acceptable salt or solvate thereof, wherein R²⁰ is an optionally substituted aryl.
9. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof wherein R¹ is optionally substituted C₁-C₆alkyl and R² is H.
10. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof wherein R⁴ and R⁵ are each optionally substituted C₁-C₆alkyl, R⁶ and R⁷ are each hydrogen, and R⁸ is -C(O)OR²⁵.
11. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R³⁰ is optionally substituted -O-(C₁-C₄alkylene)-(C₂-C₉heterocycloalkyl) and n is 0.
12. The compound of claim 1, wherein the pharmaceutically acceptable salt is hydrochloric acid.

13. The compound, or a pharmaceutically acceptable salt or solvate thereof, of claim 1 selected from:




14. A compound having the structure:



or a pharmaceutically acceptable salt or solvate thereof.

15. The compound according to claim 14 having the structure:



wherein the pharmaceutically acceptable salt is formed with hydrochloric acid.

16. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, excipient or binder, and a compound of claim 1; or a pharmaceutically acceptable salt or solvate thereof.